FEATURED NEWS

• HDA Statement on COVID-19 Emergency Relief Package

  December 22, 2020

  HDA President and CEO Chester “Chip” Davis, Jr., released a statement commenting on passage of the COVID-19 emergency relief package by the U.S. House of Representatives and the U.S. Senate.

• HDA Statement on FDA Authorization of Moderna Vaccine

  December 18, 2020

  HDA President and CEO Chester “Chip” Davis, Jr., released a statement following the U.S. Food and Drug Administration’s (FDA) granting of an Emergency Use Authorization for the Moderna COVID-19 vaccine candidate.

• HDA Statement on FDA Authorization of First COVID-19 Vaccine

  December 11, 2020

  HDA President and CEO Chester “Chip” Davis, Jr., released the following statement on the U.S. Food and Drug Administration’s (FDA) decision to grant Emergency Use Authorization of the first COVID-19 vaccine, manufactured by Pfizer and BioNTech.

• HDA Research Foundation Quantifies Efficiencies Provided by Specialty Rx Distributors

  December 10, 2020

  New data released today by the HDA Research Foundation illustrate the continued supply chain efficiencies generated by HDA-member specialty distributors. According to the latest edition of Specialty Pharmaceutical Distribution: Facts, Figures and Trends, specialty distributors are a vital nexus between 176 manufacturers and more than 49,000 provider ship-to points for administration or dispensing to patients.

• AAOA, NHMA Release Bilingual Toolkit Focused on Prescription Opioid Safety and Pain Management

  December 8, 2020

  Allied Against Opioid Abuse (AAOA) and the National Hispanic Medical Association (NHMA) released a new suite of resources to help educate the Hispanic community about the rights, risks and responsibilities associated with prescription opioids. The toolkit was developed by an advisory committee of NHMA members and features resources available in both Spanish and English.